达格列净治疗2型糖尿病心肌病患者的临床效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (454 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy and safety of Dapagliflozin in the treatment of type 2 diabetic cardiomyopathy.Methods A total of 80 patients with type 2 diabetic cardiomyopathy who were admitted to Hubei Provincial Hospital of Integrated Chinese and Western Medicine from March 2018 to December 2020 were selected as the research subjects.They were divided into treatment group and control group by random number table method,with 40 patients in each group.The control group received conventional medical treatment,and the treatment group was orally treated with Dagaglizin on the basis of the control group.Metabolic indexes(fasting blood glucose[FPG],2 hour postprandial blood glucose[2 h PG],glycated hemoglobin[HbA1c],total cholesterol[TC],triglyceride[TG],low-density lipoprotein[LDL-C)),blood pressure(systolic blood pressure[SBP],diastolic blood pressure[DBP])and cardiac function(left ventricle end-diastolic volume index[LVEDVI],left ventricular ejection fraction[LVEF])were compared between the two groups before and after treatment,and major adverse cardiac events were recorded.Results After treatment,the levels of FPG,2 h PG and HbA1c in the treatment group were lower than those in the control group,the differences were statistically significant(P＜0.05).After treatment,there were no significant differences in TC,TG and LDL-C levels between two groups(P＞0.05).After treatment,SBP and DBP in the treatment group were lower than those in the control group,the differences were statistically significant(P＜0.05).After treatment,the LVEDVI and LVEF of the treatment group were higher than those of the control group,the differences were statistically significant(P＜0.05).The total incidence of major adverse cardiac events in the treatment group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion In the treatment of type 2 diabetic cardiomyopathy,Dapagliflozin can not only effectively improve the metabolic indexes of patients such as blood glucose and blood pressure,but also improve the cardiac function of patients and reduce the occurrence of adverse cardiac events.The clinical treatment effect is significant,which is worthy of popularization and application.

Key words： Dapagliflozin Diabetes mellitus Cardiomyopathy Cardiac function

Received: 08 June 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I11/45

[2]	Tan Y，Zhang Z，Zheng C，et al.Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies：preclinical and clinical evidence[J].Nat Rev Cardiol，2020，17（9）：585-607.
[3]	邱俊霖，罗说明，周智广.糖尿病性心脏病研究进展[J].中国动脉硬化杂志，2020，28（8）：679-687.
[4]	Kaplinsky E.DAPA-HF trial：dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure[J].Drugs Context，2020，9：2019-11-3.
[5]	李欢，杨茂光，何扬芳，等.SGLT-2 抑制剂在糖尿病伴慢性肾脏病结局中的作用进展[J].中国实验诊断学，2021，25（1）：137-140.
[6]	American Diabetes A.Diagnosis and classification of diabetes mellitus[J].Diabetes Care，2010，33（Suppl 1）：S62-S69.
[7]	Maya L，Villarreal FJ.Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis[J].J Mol Cell Cardiol，2010，48（3）：524-529.
[1]	Lorenzo-Almoros A，Cepeda-Rodrigo JM，Lorenzo O.Diabetic cardiomyopathy[J].Rev Clin Esp，2020，24：S0014-2565（20）30025-4.
[8]	罗雪婷，徐昕.糖尿病心肌病与心肌代谢研究进展[J].中国老年学杂志，2020，40（13）：2891-2895.
[9]	Bastin M，Andreelli F.The gut microbiota and diabetic cardiomyopathy in humans[J].Diabetes Metab，2020，46（3）：197-202.
[10]	Athithan L，Gulsin GS，McCann GP，et al.Diabetic cardiomyopathy：Pathophysiology，theories and evidence to date[J].World J Diabetes，2019，10（10）：490-510.
[11]	Fadini GP，Tentolouris N，Caballero Mateos I，et al.A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe[J].Diabetes Ther，2020，11（2）：423-436.
[12]	赵惟超，项荣武，杜闪闪，等.达格列净治疗2型糖尿病有效性及安全性的Meta分析[J].沈阳药科大学学报，2017，34（10）：917-928.
[13]	Bailey CJ，Gross JL，Hennicken D，et al.Dapagliflozin addon to metformin in type 2 diabetes inadequately controlled with metformin：a randomized，double-blind，placebo-controlled 102-week trial[J].BMC Med，2013，11：43.
[14]	Weber MA，Mansfield TA，Alessi F，et al.Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade[J].Blood Press，2016，25（2）：93-103.
[15]	Karg MV，Bosch A，Kannenkeril D，et al.SGLT-2-inhibition with dapagliflozin reduces tissue sodium content：a randomised controlled trial[J].Cardiovasc Diabetol，2018，17（1）：5.
[16]	Vasilakou D，Karagiannis T，Athanasiadou E，et al.Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes：a systematic review and meta-analysis[J].Ann Intern Med，2013，159（4）：262-274.
[17]	Dziuba J，Alperin P，Racketa J，et al.Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes[J].Diabetes Obes Metab，2014，16（7）：628-635.
[18]	Furtado RHM，Bonaca MP，Raz I，et al.Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction[J].Circulation，2019，139（22）：2516-2527.
[19]	关清华，程岚，旷劲松.糖尿病肾病患者应用达格列净的临床疗效[J].中国现代医生，2021，59（2）：4-7.
[20]	刘林，王薇，张婷婷，等.达格列净对2型糖尿病患者血、尿电解质及尿酸影响的病例观察[J].中国糖尿病杂志，
20	20，28（5 ）：345-349.